Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.

By C. Griffiths, K. Reich, M. Lebwohl, P. C. van de Kerkhof, C. Paul, A. Menter, G. Cameron, J. Erickson, Lu Zhang, R. Secrest and 6 more. The Lancet, 2015

816 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/8581542db4280024b6e91f63a13cc563b718a36a